Upstream Bio, Inc. Asset Resilience Ratio
Upstream Bio, Inc. asset resilience ratio. Upstream Bio, Inc. (UPB) has an Asset Resilience Ratio of 64.70% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Upstream Bio, Inc. (UPB) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Upstream Bio, Inc. (2022–2025)
Asset resilience ratio of Upstream Bio, Inc. from 2022 to 2025. This chart shows how Upstream Bio, Inc.'s Asset Resilience Ratio has changed over time. Read UPB total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Upstream Bio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Upstream Bio, Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $181.91 Million | 64.7% |
| Total Liquid Assets | $181.91 Million | 64.70% |
Asset Resilience Insights
- Very High Liquidity: Upstream Bio, Inc. maintains exceptional liquid asset reserves at 64.70% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Upstream Bio, Inc. Industry Peers by Asset Resilience Ratio
Compare Upstream Bio, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Upstream Bio, Inc. Asset Resilience Ratio by Year (2022–2025)
Upstream Bio, Inc. asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for Upstream Bio, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 67.82% | $239.93 Million | $353.77 Million | +37.81pp |
| 2024-12-31 | 30.01% | $144.56 Million | $481.72 Million | -41.64pp |
| 2023-12-31 | 71.65% | $83.98 Million | $117.20 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $18.48 Million | -- |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.… Read more